NCT01998204已完成不适用
Requirement of Propofol for Induction of Unconsciousness in Patients With Parkinson's Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Consciousness status
研究概览
简要总结
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease. The investigators clinical experience showed a trend of delayed emergence among patients undergoing deep brain stimulator (DBS) implantation and pulse generator placement under general anesthesia. Abnormal pharmacodynamics might be present among these patients, which had never been investigated.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement under general anesthesia
- •non-Parkinsonian patients without Parkinson's disease undergoing intracranial surgery under general anesthesia
排除标准
- •ASA score higher than Class III
- •predicted difficult airway
- •hearing impairment
- •inability to corporate with instruction
- •alcohol or drug abuser
- •patients refusing to provide informed consent
结局指标
主要结局
Consciousness status
时间窗: Participants will be monitored during the period of propofol infusion, an expected average of less than 10 min
Consciousness status is evaluated by the observer's assessment of alertness and sedation score (OAA/S).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Fecal Microbiota Transplantation for Parkinson's DiseaseParkinson DiseaseNCT03808389University Ghent49
招募中
不适用
Non-invasive Detection of Volatile Metabolites in Parkinson's DiseaseParkinson DiseaseNCT06453226Imperial College London120
招募中
2 期
Montelukast in Parkinson DiseaseParkinson DiseaseNCT06113640Mostafa Bahaa60
已完成
2 期
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseParkinsons Disease With DementiaParkinson DiseaseNCT02954978Georgetown University75
已完成
3 期
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaIdiopathic Parkinson's DiseaseNCT00627640Newron Pharmaceuticals SPA549